ClinicalTrials.govpublic full text
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
non-small-cell lung cancer, pdl1≥50%, advanced stage, pembrolizumab, chemotherapy-pembrolizumab combination, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 982245
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.